Pathologists can make a solid case for introducing an emerging technology into their laboratory—even one without a reimbursement code—by creating a business plan, according to Dr. Wendy Wells, the chair of pathology and laboratory medicine at Dartmouth-Hitchcock Health System in Lebanon, New Hampshire. Dr. Wells spoke about creating such a business plan for ex vivo microscopy earlier this year at CAP17. In this CAPcast interview, Dr. Wells will discuss this emerging technology and the important components of a business plan, including establishing financial justification for a technology that is not yet reimbursable. For more on emerging technologies such as in vivo and ex vivo microscopy, visit the CAP IVM Topic Center: http://capatholo.gy/2zDnJzY.